Galecto Hosting Expert Perspectives Webinar on the Current Myelofibrosis Treatment Landscape and Potential Future Treatments
June 02, 2021 08:00 ET
|
Galecto, Inc.
BOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
Galecto Appoints Garrett Winslow as General Counsel
May 11, 2021 08:00 ET
|
Galecto, Inc.
BOSTON, May 11, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
Galecto to Present at Upcoming Investor Conferences and Host Myelofibrosis Key Opinion Leader Event
May 06, 2021 08:00 ET
|
Galecto, Inc.
BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
Galecto Reports First Quarter Financial Results and Provides a Corporate Update
May 04, 2021 08:30 ET
|
Galecto, Inc.
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
Galectin-3 has a key role in Gastric Cancer
April 15, 2021 08:00 ET
|
Galecto, Inc.
BOSTON, April 15, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
Galecto Reports Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update
March 29, 2021 08:30 ET
|
Galecto, Inc.
BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today...
UPDATE: Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139
March 23, 2021 10:26 ET
|
Galecto, Inc.
BOSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it will host...
Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139
March 23, 2021 08:30 ET
|
Galecto, Inc.
BOSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it will host...
Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications
March 15, 2021 07:30 ET
|
Galecto, Inc.
BOSTON, March 15, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that an...
Galecto to Present at Upcoming Investor Conferences
February 09, 2021 08:00 ET
|
Galecto, Inc.
BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced Hans Schambye,...